Teleflex's portfolio reset is pressuring results, but a cheaper valuation and divestiture proceeds could reshape its outlook over the next 6-12 months.
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.
Teleflex beats Q1 earnings and revenue estimates, but steep margin declines and a 52.1% drop in operating profit pressure shares.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Stuart A. Randle CEO | XHAN Exchange | US8793691069 ISIN |
| US Country | 14,100 Employees | 22 May 2026 Last Dividend | 17 Jun 1997 Last Split | 18 Feb 1988 IPO Date |
Teleflex Incorporated is a global leader in the development, manufacturing, and supply of single-use medical devices for diagnostic and therapeutic procedures in critical care and surgical applications. The company has a rich history dating back to 1943 and is headquartered in Wayne, Pennsylvania. Serving hospitals, healthcare providers, medical device manufacturers, and the home care market, Teleflex aims to improve the health and quality of life of patients worldwide with its innovative medical technologies.